Randall L Davis
Overview
Explore the profile of Randall L Davis including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
29
Citations
286
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Davis R, Grotjahn S, Koenig B, Buck D, Weaver 3rd J
Pharmacol Rep
. 2024 Nov;
77(1):295-301.
PMID: 39612133
Background: Phytochemicals derived from the plant Cannabis sativa hold promise in terms of medicinal value. Cannabinoids such as Δ-tetrahydrocannabinol (THC), cannabidiol (CBD), and cannabinol (CBN) are arguably the best characterized...
2.
Hodge K, Buck D, Das S, Davis R
J Inflamm (Lond)
. 2024 Sep;
21(1):33.
PMID: 39223594
Background: Inflammation and neuroinflammation are integral to the progression and severity of many diseases and are strongly associated with cardiovascular disease, cancer, autoimmune disorders, neurodegenerative disease, and neuropsychiatric disorders. These...
3.
Marmouzi I, Myers S, Buck D, Davis R, Arias H
Int J Biochem Cell Biol
. 2023 Mar;
158:106405.
PMID: 36966906
We studied, using a combination of animal and cellular models, the glial mechanisms underlying the anti-neuropathic and anti-inflammatory properties of PAM-2 [(E)-3-furan-2-yl-N-p-tolyl-acrylamide], a positive allosteric modulator of α7 nicotinic acetylcholine...
4.
Myers S, McCracken K, Buck D, Curtis J, Davis R
J Inflamm (Lond)
. 2023 Jan;
20(1):4.
PMID: 36698151
Background: Inflammation is present in neurological and peripheral disorders. Thus, targeting inflammation has emerged as a viable option for treating these disorders. Previous work indicated pretreatment with beta-funaltrexamine (β-FNA), a...
5.
Myers S, McCracken K, Buck D, Curtis J, Davis R
Inflammopharmacology
. 2022 Dec;
31(1):349-358.
PMID: 36527567
Neuroinflammation is involved in a wide range of brain disorders, thus there is great interest in identifying novel anti-inflammatory agents to include in therapeutic strategies. Our previous in vitro studies...
6.
Burch K, McCracken K, Buck D, Davis R, Sloan D, Curtis K
Front Physiol
. 2022 Jan;
12:800266.
PMID: 35069259
Although increasing research focuses on the phenomenon of body weight gain in women after menopause, the complexity of body weight regulation and the array of models used to investigate it...
7.
Davis R
J Neurochem
. 2019 Mar;
149(1):9-11.
PMID: 30874310
The pathophysiology of major depressive disorders is not completely understood. In this issue of Journal of Neurochemistry, Ni and colleagues investigate the role of cyclic adenosine monophosphate response element-binding protein...
8.
Curtis K, McCracken K, Espinosa E, Ong J, Buck D, Davis R
Neurochem Res
. 2018 Jul;
43(9):1802-1813.
PMID: 30030770
Systemic inflammation is present in obesity and emerging evidence, primarily from studies using male rodents fed high-fat diets, suggests neuroimmune signaling also is involved. We investigated early changes in neuroimmune...
9.
Davis R, Stevens C, Curtis J
Physiol Behav
. 2017 Jan;
173:52-60.
PMID: 28130086
Brain pathologies such as neurodegenerative diseases, infection, traumatic brain injury, and mood disorders produce enormous personal and economic burdens. It is well established that neuroinflammation plays an important role in...
10.
Davis R, Das S, Curtis J, Stevens C
Eur J Pharmacol
. 2015 May;
762:193-201.
PMID: 26007645
Opioid-immune crosstalk occurs when opioid drugs alter the activity of the immune system. In this study, the opioid antagonist β-funaltrexamine (β-FNA) decreases the expression and release of an inflammatory chemokine,...